OtherBasic Science (Animal or Phantoms)
Preclinical Evaluation of 111In-labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-positive Cancer Models
Siddesh V Hartimath, Elahe Alizadeh, Viswas Raja Solomon, Rufael Chekol, Wendy Bernhard, Wayne Hill, Angel Parada Casaco, Kris Barreto, Clarence Ronald Geyer and Humphrey Fonge
Journal of Nuclear Medicine January 2019, jnumed.118.220095; DOI: https://doi.org/10.2967/jnumed.118.220095
Siddesh V Hartimath
1 University of Saskatchewan, Canada;
Elahe Alizadeh
1 University of Saskatchewan, Canada;
Viswas Raja Solomon
1 University of Saskatchewan, Canada;
Rufael Chekol
1 University of Saskatchewan, Canada;
Wendy Bernhard
1 University of Saskatchewan, Canada;
Wayne Hill
1 University of Saskatchewan, Canada;
Angel Parada Casaco
2 Center for Molecular Immunology, Canada
Kris Barreto
1 University of Saskatchewan, Canada;
Clarence Ronald Geyer
1 University of Saskatchewan, Canada;
Humphrey Fonge
1 University of Saskatchewan, Canada;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 3
March 1, 2024
Preclinical Evaluation of 111In-labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-positive Cancer Models
Siddesh V Hartimath, Elahe Alizadeh, Viswas Raja Solomon, Rufael Chekol, Wendy Bernhard, Wayne Hill, Angel Parada Casaco, Kris Barreto, Clarence Ronald Geyer, Humphrey Fonge
Journal of Nuclear Medicine Jan 2019, jnumed.118.220095; DOI: 10.2967/jnumed.118.220095
Preclinical Evaluation of 111In-labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-positive Cancer Models
Siddesh V Hartimath, Elahe Alizadeh, Viswas Raja Solomon, Rufael Chekol, Wendy Bernhard, Wayne Hill, Angel Parada Casaco, Kris Barreto, Clarence Ronald Geyer, Humphrey Fonge
Journal of Nuclear Medicine Jan 2019, jnumed.118.220095; DOI: 10.2967/jnumed.118.220095
Jump to section
Related Articles
Cited By...
- No citing articles found.